Scarica l'app Stockscreener
82.47
1.14%
-0.95
Dopo l'orario di chiusura:
86.67
4.20
+5.09%
Precedente Chiudi:
$83.42
Aprire:
$83.56
Volume 24 ore:
582.94K
Relative Volume:
1.08
Capitalizzazione di mercato:
$8.82B
Reddito:
$612.78M
Utile/perdita netta:
$-86.37M
Rapporto P/E:
-51.22
EPS:
-1.61
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
-9.94%
1M Prestazione:
+5.27%
6M Prestazione:
+26.88%
1 anno Prestazione:
+44.20%
Intervallo 1D:
$81.83
$83.61
Intervallo di 1 settimana:
$81.83
$91.52
Portata 52W:
$56.83
$93.45
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Nome
Intra Cellular Therapies Inc
Settore
Telefono
(646) 440-9333
Indirizzo
135 ROUTE 202/206, BEDMINSTER, NY
Confronta ITCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ITCI | 82.47 | 8.82B | 612.78M | -86.37M | -62.91M | -1.61 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-11 | Iniziato | TD Cowen | Outperform |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2022-08-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-22 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Iniziato | Goldman | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-10 | Iniziato | Goldman | Buy |
| 2020-02-20 | Iniziato | Evercore ISI | Outperform |
| 2020-01-31 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-12 | Iniziato | Jefferies | Buy |
| 2018-02-26 | Iniziato | JP Morgan | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-11-08 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-09-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-09-29 | Downgrade | SunTrust | Buy → Neutral |
Mostra tutto
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
Entropy Technologies LP Acquires Shares of 7,116 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Simplify Asset Management Inc. Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-cellular therapies president sells $3.69 million in stock - Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Increased by Aigen Investment Management LP - MarketBeat
FMR LLC Reduces Stake in Intra-Cellular Therapies Inc - GuruFocus.com
Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month HighTime to Buy? - MarketBeat
Lisanti Capital Growth LLC Sells 24,760 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular bolsters Caplyta data with another Phase III win - MSN
Principal Financial Group Inc. Acquires 18,865 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
TimesSquare Capital Management LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
M&G Plc Invests $9.08 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High of $90.37 - Investing.com India
Intra-Cellular Therapies Stock Hits All-Time High of $90.37 By Investing.com - Investing.com UK
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - The Manila Times
Lifespeak Inc (LSPK-T) QuotePress Release - The Globe and Mail
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26% - Simply Wall St
Intra-Cellular Therapies Inc (ITCI) Trading 3.56% Higher on Nov 6 - GuruFocus.com
Positive Phase III results for Intra-Cellular’s Caplyta in schizophrenia - The Pharma Letter
Intra-Cellular Therapies Announces Positive Topline Results - GlobeNewswire
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% - Benzinga
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid market expansion - Investing.com India
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial - Reuters
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia - The Manila Times
Harbor Capital Advisors Inc. Boosts Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews - Benzinga
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for ITCI Earnings - MarketBeat
Emerald Advisers LLC Acquires 48,705 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Net Present Value Model: Intra-Cellular Therapies Inc’s Lenrispodun phosphate - GlobalData
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results - Yahoo Finance
Intra-Cellular price target raised to $135 from $130 at Cantor Fitzgerald - MSN
FY2027 Earnings Estimate for ITCI Issued By Leerink Partnrs - MarketBeat
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
abrdn plc Has $18.36 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates - MSN
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Large Decrease in Short Interest - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 By Investing.com - Investing.com Australia
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript - Insider Monkey
Intra-Cellular: Q3 Earnings Snapshot - The Pioneer
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $96.62 Average Target Price from Brokerages - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 - Investing.com India
Intra-Cellular Therapies Reports Strong Q3 Growth - TipRanks
Intra-Cellular stock target raised on Caplyta sales outlook By Investing.com - Investing.com Canada
Intra-Cellular jumps on Q3 beat as Caplyta outlook brightens - MSN
Intra-Cellular Therapies Q3 2024 Earnings Preview - MSN
Intra-Cellular stock jumps on Caplyta outlook (ITCI:NASDAQ) - Seeking Alpha
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year HighStill a Buy? - MarketBeat
Intra Cellular Therapies Inc Azioni (ITCI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.54%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):